Product Details
UDENYCA 6 MG/0.6 ML SYRINGE
Manufacturer: COHERUS BIOSCIENCES INC
MFG#: 70114-0101-01
NDC: 70114-0101-01
PID: 639467
1/UN
$1,711.16
In StockAdditional Information
| Product Name | Udenyca 6 mg/0.6 mL Syringe |
| Active Ingredient | Pegfilgrastim |
| Drug Class | Granulocyte Colony-Stimulating Factor (G-CSF) |
| Mechanism of Action | Stimulates the production of neutrophils by the bone marrow to reduce the risk of infection due to chemotherapy-induced neutropenia |
| Strength | 6 mg |
| Volume | 0.6 mL |
| Route of Administration | Subcutaneous (SC) injection |
| Side Effects | Bone pain, headache, injection site reactions, splenic rupture, acute respiratory distress syndrome (ARDS) |
| Precautions | Monitor for signs of splenic rupture, ARDS, and allergic reactions |
| Storage | Store between 2°C and 8°C (refrigerated), do not freeze |
| Packaging | Prefilled syringe containing 6 mg of pegfilgrastim in 0.6 mL of solution |
| Uses | Prevention of infection due to neutropenia in chemotherapy patients |
Description
Udenyca 6 mg/0.6 mL Syringe is a biologic medication primarily used to reduce the incidence of infection in cancer patients receiving chemotherapy. It contains the active ingredient pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim stimulates the bone marrow to produce white blood cells, specifically neutrophils, thereby helping to prevent febrile neutropenia, a condition characterized by a low white blood cell count and fever, which can be a life-threatening side effect of chemotherapy.
The medication is administered as a subcutaneous injection, typically given once per chemotherapy cycle, at least 24 hours after chemotherapy. The exact dosing schedule is determined based on the patient's treatment regimen and specific medical needs. Udenyca helps to minimize the duration of neutropenia and reduce the risk of infection in patients undergoing chemotherapy.
Common side effects include bone pain, headache, and injection site reactions, while more serious adverse effects such as splenic rupture and acute respiratory distress syndrome (ARDS) are rare but possible. Patients receiving Udenyca should be monitored for signs of these severe side effects.
Frequently Asked Questions (FAQs)
The cost of UDENYCA 6 MG/0.6 ML SYRINGE is $$1,711.16
UDENYCA 6 MG/0.6 ML SYRINGE is manufactured by COHERUS BIOSCIENCES INC.
You can purchase UDENYCA 6 MG/0.6 ML SYRINGE on our website at https://supplies.pipelinemedical.com/product/detail/udenyca-6-mg-0-6-ml-syringe-637909